ArticlePostepy dermatologii i alergologii2025
The clinical predictors of biochemical hyperandrogenemia and its relation to treatment resistance in women with acne.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prevalence of biochemical hyperandrogenemia (BHA) in female acne varies across studies. While certain phenotypic features may suggest hormonal evaluation, clinical predictors of BHA are unclear. Furthermore, the predictors of treatment outcome remain inconclusive, and despite common belief, no strong evidence links BHA to treatment resistance. Aim: To identify determinants of BHA and treatment response in female acne. Material and methods: Female acne patients who underwent hormonal tests (androstenedione, DHEAS04, E2, FSH, LH, free testosterone, prolactin, SHBG, TSH, total testosterone, and 17-OHP) from January 2020 to September 2022 were analysed for associations of clinical parameters with BHA, PCOS, and treatment resistance. Results: Among 86 females (mean age: 24, range: 14-41), acne categories were as follows: persistent (46.5%), adult-onset (26.7%), recurrent (19.8%), and adolescent (7%). Clinical and BHA rates were 65.1% and 70.9%, respectively. The most common elevated hormones were 17-OHP (65%) and androstenedione (40%). Hirsutism and truncal acne were associated with BHA. High DHEAS04 and menstrual irregularity were linked to the persistent category, and 17-OHP elevation was related to a chronic course. PCOS prevalence (17.4%) was associated with high DHEAS04, Free Androgen Index, TT, low E2, and hirsutism. Persistent/recurrent acne and hirsutism were associated with treatment failure. Conclusions: The persistent course and prolonged duration of acne in females, combined with hirsutism and truncal location, are associated with BHA. Patients without androgenic signs may have BHA, and PCOS diagnosis can be established through appropriate referral. Treatment response does not correlate with hormone levels; however, prolonged duration/persistent course and hirsutism predict poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.